MCID: CHR189
MIFTS: 23

Chromosome 12p Deletion

Categories: Rare diseases

Aliases & Classifications for Chromosome 12p Deletion

MalaCards integrated aliases for Chromosome 12p Deletion:

Name: Chromosome 12p Deletion 49 28
Loss of Chromosome 12p 69
Partial Monosomy 12p 49
12p Deletion 49
12p Monosomy 49
Deletion 12p 49
Monosomy 12p 49

Classifications:



External Ids:

UMLS 69 C1517955

Summaries for Chromosome 12p Deletion

MalaCards based summary : Chromosome 12p Deletion, also known as loss of chromosome 12p, is related to distal monosomy 12p and myeloma, multiple. The drugs Ethanol and Histamine have been mentioned in the context of this disorder. Affiliated tissues include eye, pancreas and myeloid.

Related Diseases for Chromosome 12p Deletion

Diseases related to Chromosome 12p Deletion via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 distal monosomy 12p 11.1
2 myeloma, multiple 9.8
3 acute lymphoblastic leukemia, childhood 9.8
4 acute lymphocytic leukemia 9.8
5 leukemia 9.8

Graphical network of the top 20 diseases related to Chromosome 12p Deletion:



Diseases related to Chromosome 12p Deletion

Symptoms & Phenotypes for Chromosome 12p Deletion

Drugs & Therapeutics for Chromosome 12p Deletion

Drugs for Chromosome 12p Deletion (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3
Oxazepam Approved Phase 4 604-75-1 4616
4
Sodium oxybate Approved Phase 4 502-85-2 5360545
5
Povidone Approved Phase 4 9003-39-8
6
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
7
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Central Nervous System Depressants Phase 4
10 Adjuvants, Anesthesia Phase 4
11 Micronutrients Phase 4
12 GABA Agents Phase 4
13 GABA Modulators Phase 4
14 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Trace Elements Phase 4
16 Tranquilizing Agents Phase 4
17 Vaccines Phase 4
18 Histamine Antagonists Phase 4
19 Anesthetics Phase 4
20 Anesthetics, General Phase 4
21 Anesthetics, Intravenous Phase 4
22 Vitamins Phase 4
23 Anti-Anxiety Agents Phase 4
24 Hypnotics and Sedatives Phase 4
25 Ergocalciferols Phase 4
26 Anti-Infective Agents Phase 4,Phase 2
27 Anti-Infective Agents, Local Phase 4
28 Psychotropic Drugs Phase 4
29 Bone Density Conservation Agents Phase 4
30 Vitamin D2 Nutraceutical Phase 4
31 Calciferol Nutraceutical Phase 4
32
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
33
Idarubicin Approved Phase 3 58957-92-9 42890
34
Pancrelipase Approved, Investigational Phase 3,Phase 2 53608-75-6
35
Salmeterol xinafoate Phase 3 94749-08-3 56801
36 Respiratory System Agents Phase 3,Phase 2
37 Adrenergic Agents Phase 3
38 Adrenergic Agonists Phase 3
39 Adrenergic beta-2 Receptor Agonists Phase 3
40 Adrenergic beta-Agonists Phase 3
41 Formoterol Fumarate Phase 3
42 Topoisomerase Inhibitors Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 3,Phase 2
44 Anti-Asthmatic Agents Phase 3
45 Anti-Bacterial Agents Phase 3,Phase 2
46 Pharmaceutical Solutions Phase 3,Phase 2
47 Etoposide phosphate Phase 3,Phase 2
48 Antibiotics, Antitubercular Phase 3,Phase 2
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
50 Autonomic Agents Phase 3,Phase 2

Interventional clinical trials:

(show all 43)

# Name Status NCT ID Phase Drugs
1 Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Completed NCT02090504 Phase 4 Sodium Oxybate (SMO);Oxazepam
2 Bioequivalence of Ethylenediamine Dihydrochloride Study Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
3 The Safety and Immune Response to Influenza Vaccination in Pregnant Women Completed NCT01514708 Phase 4
4 Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients Completed NCT00294866 Phase 4 Paricalcitol
5 Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result Completed NCT00146120 Phase 3 Idarubicin;Cytosin-Arabinosid;Etoposide;All-trans Retinoid acid
6 Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD Completed NCT00064402 Phase 3 arformoterol tartrate inhalation solution;arformoterol tartrate inhalation solution;arformoterol tartrate inhalation solution;Salmeterol;Placebo
7 Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas Recruiting NCT02514928 Phase 3
8 Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response Terminated NCT00159926 Phase 3
9 A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease Completed NCT00265122 Phase 2 Ustekinumab 90 mg;Ustekinumab 4.5 mg/kg;Placebo SC;Placebo IV
10 A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis Completed NCT00207727 Phase 2 CNTO 1275
11 Rituximab for Pulmonary Sarcoidosis Completed NCT00855205 Phase 2 Rituximab
12 A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection Completed NCT02391805 Phase 2 Entecavir;Placebo;RO6864018;Tenofovir
13 A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease Completed NCT01135511 Phase 2 CP-690,550 Eye drops;CP-690,550 Eye drops;CP-690,550 Eye drops;CP-690,550 Eye drops-vehicle;Sodium Hyaluronate
14 Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning Recruiting NCT02952716 Phase 1, Phase 2
15 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Recruiting NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
16 Cytoreductive Surgery(CRS) Plus Hyperthermic Intraoperative Peritoneal Chemotherapy(HIPC) With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer Terminated NCT01116791 Phase 2
17 Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects Completed NCT02211170 Phase 1 BIBR 796 BS, low dose;BIBR 796 BS, high dose;Placebo;Lipopolysaccharide
18 A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531 Recruiting NCT02956850 Phase 1 RO7020531
19 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Active, not recruiting NCT01703507 Phase 1 Ipilimumab
20 Maternal Serum Cytokine Levels and Angiogenic Factor Levels in IVF vs Spontaneously Conceived Pregnancies Unknown status NCT00837278
21 Genetic Disease Gene Identification Unknown status NCT00916903
22 Exercise-induced Bronchoconstriction in School Children Unknown status NCT01798823
23 Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma Completed NCT00323206
24 Polymorphism C677T MTHFR and Folate Intake in Inflammatory Biomarkers Completed NCT03186196
25 Keratinocyte Growth Factor and Cytokines in Burns. Completed NCT01302223
26 Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder Completed NCT01862653
27 0.2 ml vs. 0.5 Inseminated Volume in Donor Intrauterine Insemination Cycles: A Prospective RCT Completed NCT03006523
28 Bioavailability and Beneficial Properties of Coffee and Cocoa Bioactive Compounds Completed NCT03166540
29 Low Dose Naltrexone (LDN) Immune Monitoring Completed NCT02107014 Low Dose Naltrexone
30 Post-bypass Prophylactic IVIG in Infants and Neonates Completed NCT02043379 IVIG
31 Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition Completed NCT02743195
32 Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended? Recruiting NCT02787187
33 Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduodenectomy Recruiting NCT03081351
34 Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder Recruiting NCT02992899
35 Bringing the Practice of Mindfulness Into Nature - Preventing Mental Fatigue in Healthcare Professionals. Recruiting NCT02867657
36 Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend Recruiting NCT03309982
37 Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma Active, not recruiting NCT02097134 Melphalan
38 (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil? Active, not recruiting NCT02310789 Early Phase 1 Ivacaftor
39 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Suspended NCT01798004 cyclophosphamide;topotecan hydrochloride;cisplatin;etoposide;vincristine sulfate;doxorubicin hydrochloride;busulfan;melphalan;mesna
40 Reiki for the Management of Neuropathic Pain Terminated NCT02328703
41 Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat") Terminated NCT00764179
42 Airway Inflammatory Response During Illness in Children With Respiratory Failure Withdrawn NCT02047877
43 Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery Withdrawn NCT02671552 Early Phase 1 Perflutren Protein-Type A Microspheres

Search NIH Clinical Center for Chromosome 12p Deletion

Genetic Tests for Chromosome 12p Deletion

Genetic tests related to Chromosome 12p Deletion:

# Genetic test Affiliating Genes
1 Chromosome 12p Deletion 28

Anatomical Context for Chromosome 12p Deletion

MalaCards organs/tissues related to Chromosome 12p Deletion:

38
Eye, Pancreas, Myeloid, Liver, Kidney, Bone, Brain

Publications for Chromosome 12p Deletion

Articles related to Chromosome 12p Deletion:

# Title Authors Year
1
Chromosome 12p Deletion Spanning the GRIN2B Gene Presenting With a Neurodevelopmental Phenotype: A Case Report and Review of Literature. ( 28503605 )
2016
2
Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. ( 25831238 )
2015
3
Analysis of chromosome 12p deletion in plasma cell dyscrasias. ( 21982640 )
2012
4
ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. ( 9305598 )
1997

Variations for Chromosome 12p Deletion

Expression for Chromosome 12p Deletion

Search GEO for disease gene expression data for Chromosome 12p Deletion.

Pathways for Chromosome 12p Deletion

GO Terms for Chromosome 12p Deletion

Sources for Chromosome 12p Deletion

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....